Key Insights

Highlights

Treatment Research

3 treatments under study, led by Tocilizumab

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05168475Phase 2Terminated

Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis

Showing all 1 trials

Research Network

Common Treatments

  • Tocilizumab1
  • Infliximab1
  • Rituximab1

Active Sponsors

  • Cambridge University Hospitals NHS Foundation Trust1

Top Investigators

  • David Jayne1

    Cambridge University Hospitals NHS Foundation Trust/University of Cambridge

Related Conditions

  • Cutaneous Polyarteritis Nodosa1
  • Polyarteritis Nodosa1
  • Cogan Syndrome1
  • Giant Cell Arteritis1
  • Cryoglobulinemic Vasculitis1

Activity Timeline